136 results on '"Healy, Shannon"'
Search Results
2. TRAF3 loss-of-function reveals the noncanonical NF-κB pathway as a therapeutic target in diffuse large B cell lymphoma
3. TMEM30A loss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
4. Tumor-associated antigen PRAME exhibits dualistic functions that are targetable in diffuse large B cell lymphoma
5. Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation
6. Supplementary Data from Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
7. Data from Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
8. Age related medication for addiction treatment (MAT) use for opioid use disorder among Medicaid-insured patients in New York
9. An RCOR1 loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
10. TRAF3 Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma
11. Mapping Glacier Ablation With a UAV in the North Cascades: A Structure-from-Motion Approach
12. Dynamical effects of transcriptional pause-prone sites
13. Non-coding NFKBIZ 3′ UTR mutations promote cell growth and resistance to targeted therapeutics in diffuse large B-cell lymphoma
14. RNA-dependent dynamic histone acetylation regulates MCL1 alternative splicing
15. Emerging Geospatial Technologies in Environmental Research, Education, and Outreach
16. Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings
17. The Tumor Associated Antigen PRAME Exhibits Dualistic Functions That Are Targetable in Diffuse Large B-Cell Lymphoma
18. TRAF3 Loss Drives Alternative NF-κB Pathway Activation in Diffuse Large B-Cell Lymphoma
19. Nfkbiz 3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
20. Abstract PO-18: Comprehensive correlation between genetic alterations in DLBCL and deregulated activation of the PI3K-AKT pathway isolates unique players in lymphoma dissemination and inferior outcome
21. Abstract PO-32: NFKBIZ 3′ UTR mutations confer selective growth advantage and affect drug response in diffuse large B-cell lymphoma
22. Immediate early response genes and cell transformation
23. Belief patterns and drug use in a sample of Brazilian youth: an exploratory latent class analysis
24. Single-Cell Transcriptome Analysis Reveals Disease-Defining T-cell Subsets in the Tumor Microenvironment of Classic Hodgkin Lymphoma
25. Predictors of Medication Utilization for Opioid Use Disorder Among Medicaid‐Insured HIV Patients in New York
26. NFKBIZ3′ UTR Mutations Confer Selective Growth Advantage and Activate Genes with Therapeutic Implications in Diffuse Large B-Cell Lymphoma
27. Nonenzymatic biotinylation of histone H2A
28. Abstract 3480:TMEM30Aloss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
29. Somatic PRAME Deletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma
30. Hepatitis C Virus Screening among Medicaid-Insured Individuals with Opioid Use Disorder across Substance Use Disorder Treatment Settings.
31. Structural impact of human and Escherichia coli biotin carboxyl carrier proteins on biotin attachment
32. Mitogen-induced distinct epialleles are phosphorylated at either H3S10 or H3S28, depending on H3K27 acetylation
33. TMEM30Aloss-of-function mutations drive lymphomagenesis and confer therapeutically exploitable vulnerability in B-cell lymphoma
34. Structural Impact of Human and Escherichia coliBiotin Carboxyl Carrier Proteins on Biotin Attachment
35. Abstract 3941: Recurrent IL4R mutations in primary mediastinal large B cell lymphoma
36. TRAF3Loss-of-Function Reveals the Non-Canonical NF-Κb Pathway As a Therapeutic Target in Diffuse Large B-Cell Lymphoma
37. RNA-dependent dynamic histone acetylation regulates MCL1 alternative splicing
38. Crystallographic studies of Thermoanaerobacterium thermosulfurigenes beta-galactosidase
39. Mitogen- and Stress-Activated Protein Kinases 1 and 2 Are Required for Maximal Trefoil Factor 1 Induction
40. Histone H3 phosphorylation, immediate-early gene expression, and the nucleosomal response: a historical perspective1This article is part of Special Issue entitled Asilomar Chromatin and has undergone the Journal’s usual peer review process.
41. Genome wide study of NF-Y type CCAAT boxes in unidirectional and bidirectional promoters in human and mouse
42. Cell-to-cell diversity in protein levels of a gene driven by a tetracycline inducible promoter
43. Role of MSK1 in the Malignant Phenotype of Ras-transformed Mouse Fibroblasts
44. Effects of Transcriptional Pausing on Gene Expression Dynamics
45. Tuning cell differentiation patterns and single cell dynamics by regulating proteins’ functionalities in a toggle switch
46. Biotin is not a natural histone modification
47. An RCOR1loss–associated gene expression signature identifies a prognostically significant DLBCL subgroup
48. TRAF3Loss Drives Alternative NF-κB Pathway Activation in Diffuse Large B-Cell Lymphoma
49. Nfkbiz3′ UTR Mutations Confer Selective Growth Advantage and Affect Drug Response in Diffuse Large B-Cell Lymphoma
50. Somatic PRAMEDeletions Are Associated with Decreased Immunogenicity, Apoptosis Resistance and Poor Outcomes in Diffuse Large B-Cell Lymphoma
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.